调节性T细胞在急性心肌梗死中的调控机制及研究进展  

Advances in research on the regulatory mechanism of regulatory T cells in acute myocardial infarction

作　　者：李佳玉 辛延国 李卫萍[1] 陈晖[1] 李虹伟[1] Li Jiayu;Xin Yanguo;Li Weiping;Chen Hui;Li Hongwei(Department of Cardiology,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China)

机构地区：[1]首都医科大学附属北京友谊医院心血管内科,100050

出　　处：《中国心血管杂志》2023年第4期403-406,共4页Chinese Journal of Cardiovascular Medicine

基　　金：科技创新2030——新一代人工智能重大项目(2021ZD0111000);国家自然科学基金面上项目(82070357);北京市重点实验室。

摘　　要：急性心肌梗死(AMI)给免疫系统带来了重大挑战,包括控制早期炎症反应、促进中晚期心肌纤维化形成等。研究表明,CD4^(+)CD25^(+)Foxp^(3+)调节性T(Treg)细胞可能在介导心肌梗死后炎症抑制、改善心室重构、促进缺血后新生血管形成等方面扮演重要角色,其靶向治疗可能为预防和治疗心血管疾病提供一种新思路。Acute myocardial infarction(AMI)poses major challenges to the immune system,including controlling early inflammatory responses and promoting myocardial fibrosis in the middle and late phases.Studies indicated that CD4^(+)CD25^(+)Foxp^(3+)regulatory T(Treg)cells are indispensable to inflammatory suppression after AMI,attenuating ventricular remodeling,and promoting postischemic neovascularization.The targeted therapies of Treg cells may provide a promising new approach for the prevention and treatment of cardiovascular diseases.

关 键 词：调节性T细胞 急性心肌梗死 再灌注损伤 免疫调节 炎症反应 

分 类 号：R542.22[医药卫生—心血管疾病]